Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359708 | 0.84 | SMN1; SMN2 (0.54) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL11199323 | 0.83 | PARP10 (0.54) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL493397 | 0.79 | HRH1 (0.52) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL18997786 | 0.79 | SMN1; SMN2 (0.46) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL740907 | 0.79 | SMN1; SMN2 (0.49) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL6223872 | 0.79 | SMN1; SMN2 (0.59) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL29574868 | 0.78 | MAPT (0.43) | PARP10SMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL7189404 | 0.78 | SMN1; SMN2 (0.51) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| Hydrochloric Acid SCHEMBL7607601 | 0.77 | SMN1; SMN2 (0.58) | PARP10SMN1; SMN2NPC1RAB9ALMNA | |
| Hydrochloric Acid SCHEMBL27710379 | 0.77 | SMN1; SMN2 (0.50) | PARP10SMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2064182-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008006703-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878721-A1 | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | NOVO NORDISK A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-1802623-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | Novo Nordisk A/S (DK) | 2007-07-04 | — | — | EP | disclosed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | disclosed |
| WO-2006040329-A1 | 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| EP-1618090-A1 | 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004089896-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD17B1 | PARP10 1886/4885SMN1; SMN2 2477/4885NPC1 343/4885 |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | PARP10 1005/4885SMN1; SMN2 3206/4885NPC1 531/4885 |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | HSD11B1, HSD3B1, HSD17B1 | PARP10 2422/4885SMN1; SMN2 2622/4885NPC1 383/4885 |
| US-20090325932-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD11B1, HSD3B1, HSD17B1 | PARP10 1237/4885SMN1; SMN2 3766/4885NPC1 945/4885 |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | HSD11B1, HSD3B1, HSD17B1 | PARP10 1886/4885SMN1; SMN2 2477/4885NPC1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.